Capital Advisors Inc. OK Has $250,000 Position in Gilead Sciences, Inc. $GILD

Capital Advisors Inc. OK increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,258 shares of the biopharmaceutical company’s stock after buying an additional 179 shares during the quarter. Capital Advisors Inc. OK’s holdings in Gilead Sciences were worth $250,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Valeo Financial Advisors LLC grew its stake in shares of Gilead Sciences by 26.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 13,262 shares of the biopharmaceutical company’s stock worth $1,470,000 after acquiring an additional 2,795 shares in the last quarter. Knights of Columbus Asset Advisors LLC grew its position in Gilead Sciences by 1.5% in the second quarter. Knights of Columbus Asset Advisors LLC now owns 28,863 shares of the biopharmaceutical company’s stock valued at $3,200,000 after purchasing an additional 415 shares in the last quarter. Merit Financial Group LLC increased its stake in Gilead Sciences by 64.1% in the 2nd quarter. Merit Financial Group LLC now owns 47,951 shares of the biopharmaceutical company’s stock valued at $5,316,000 after buying an additional 18,722 shares during the last quarter. Simplicity Wealth LLC lifted its position in Gilead Sciences by 158.0% during the 2nd quarter. Simplicity Wealth LLC now owns 11,108 shares of the biopharmaceutical company’s stock worth $1,232,000 after buying an additional 6,802 shares in the last quarter. Finally, Carolina Wealth Advisors LLC lifted its position in Gilead Sciences by 599.3% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 979 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 839 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $113.58 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $140.93 billion, a P/E ratio of 22.63, a P/E/G ratio of 0.77 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83. The stock has a 50 day moving average of $114.36 and a 200-day moving average of $110.01.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the firm posted $2.01 EPS. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences’s payout ratio is presently 62.95%.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,402,130 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a report on Friday, July 25th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. UBS Group upped their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Rothschild & Co Redburn raised their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.